The statistics are stark: One in eight American women will grapple with a breast cancer diagnosis in her lifetime. Per the latest 2025 report by the American Cancer Society, current treatments don't always cut it. University of Cincinnati professor Xiaoting Zhang is on the front lines in the battle against this pervasive illness, taking aim at one of the toughest challenges in cancer therapy, drug resistance.
Zhang, who holds the title of John and Gladys Strauss Endowed Chair in Cancer Research and is the director of UC’s Breast Cancer Research Program, knows the stakes are high. He's not just conducting research, his latest breakthrough in understanding drug resistance in breast cancer has been documented in top-tier scientific journals. Moreover, Zhang’s venture, RNA Nanotherapeutics, is making strides. It leverages cutting-edge RNA nanotechnology to tackle treatment resistance, and it’s drawing on the entrepreneurial spirit and support of UC's 1819 Innovation Hub, according to UC News in a recent report.
The core of Zhang’s approach hinges on a key gene pertinent to breast cancer treatment resistance. Through extensive research, he and his team have uncovered mechanisms that cancer cells use to evade therapies. His patented method uses RNA nanotechnology to intercept these resistance pathways and allow treatments to work more effectively.
RNA Nanotherapeutics, Zhang's brainchild, isn't just a lab project, it’s a promising startup that melds scientific discovery with entrepreneurial acumen. The company enjoys the unique position of being nurtured within the confines of an academic institution, yet operates with the agility of a biotech startup. It's important to note, this approach could be a game-changer, not just for breast cancer, but for oncology as a whole.
